Financial Summary for Q1 FY2026 Ending December 31 [IFRS] (Consolidated)

Performance Overview

In Q1 FY2026 ending December, revenue reached JPY 11,256 million (up 69.4% YoY), and operating income turned positive to JPY 3,244 million. Quarterly profit was positive at JPY 1,793 million, and the equity ratio attributable to owners of the parent rose to 47.8%. The main drivers of revenue growth were strong sales of Pivlats® and Cubivic®, along with a significant increase in milestone income. Research and development expenses were JPY 3,028 million, down compared to the same period last year, with ongoing cost reduction initiatives.

Outlook and Business Strategy

Full-year earnings guidance for FY2026 ending December forecasts revenue between JPY 33,800 million and JPY 48,800 million, with operating income ranging from JPY 700 million to JPY 15,700 million. Revenue from Pivlats® and Cubivic® is expected to be between JPY 13.8 billion and JPY 14.2 billion, and JPY 5 billion to JPY 6 billion, respectively. New partnerships and increased milestone income are expected to contribute to performance. We are advancing new drug development leveraging the drug discovery platform technology NxWave™, as well as late-stage clinical development in the Asia-Pacific region, aiming for strategic growth.